An open-label, single-arm phase two trial of gefitinib in patients with advanced or metastatic castration-resistant prostate cancer

Carmel Pezaro, Mark A. Rosenthal, Howard Gurney, Ian D. Davis, Craig Underhill, Michael J. Boyer, Dusan Kotasek, Benjamin Solomon, Guy C. Toner

Research output: Contribution to journalArticleResearchpeer-review

Abstract

OBJECTIVE: To determine whether the oral epidermal growth factor receptor (EGFR) inhibitor gefitinib (ZD1839, Iressa®) has clinical efficacy in patients with castration-resistant prostate cancer (CRPC). METHODS: Multicenter open-label phase 2 study. Fifty-one male patients with CRPC and rising PSA levels were enrolled to obtain the target enrollment of 38 patients who completed at least 3 months of treatment with continuous gefitinib 500 mg/d. The primary end point was the prostate-specific antigen (PSA) response rate, as defined by a confirmed 50% decline in serum PSA. RESULTS: One patient had a confirmed PSA response, giving a response rate of 2.0% (95% CI 0.1-10.4%). The median time to progression was 28 days and the median time on study was 85 days. The majority of patients had a stable performance status while on study. Of the 51 patients who received at least 1 dose of gefitinib, 13 patients had a dose reduction and 9 patients withdrew because of an adverse event. CONCLUSIONS: There was minimal evidence of single-agent gefitinib activity in CRPC. The treatment was associated with clinically relevant toxicities, which responded to dose interruption or reduction.

LanguageEnglish
Pages338-341
Number of pages4
JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
Volume32
Issue number4
DOIs
Publication statusPublished - Aug 2009
Externally publishedYes

Fingerprint

Castration
Prostatic Neoplasms
Prostate-Specific Antigen
gefitinib
Epidermal Growth Factor Receptor
Therapeutics
Serum

Cite this

Pezaro, Carmel ; Rosenthal, Mark A. ; Gurney, Howard ; Davis, Ian D. ; Underhill, Craig ; Boyer, Michael J. ; Kotasek, Dusan ; Solomon, Benjamin ; Toner, Guy C. / An open-label, single-arm phase two trial of gefitinib in patients with advanced or metastatic castration-resistant prostate cancer. In: American Journal of Clinical Oncology: Cancer Clinical Trials. 2009 ; Vol. 32, No. 4. pp. 338-341.
@article{31086bf32cd24661a85d70c42f00c6fe,
title = "An open-label, single-arm phase two trial of gefitinib in patients with advanced or metastatic castration-resistant prostate cancer",
abstract = "OBJECTIVE: To determine whether the oral epidermal growth factor receptor (EGFR) inhibitor gefitinib (ZD1839, Iressa{\circledR}) has clinical efficacy in patients with castration-resistant prostate cancer (CRPC). METHODS: Multicenter open-label phase 2 study. Fifty-one male patients with CRPC and rising PSA levels were enrolled to obtain the target enrollment of 38 patients who completed at least 3 months of treatment with continuous gefitinib 500 mg/d. The primary end point was the prostate-specific antigen (PSA) response rate, as defined by a confirmed 50{\%} decline in serum PSA. RESULTS: One patient had a confirmed PSA response, giving a response rate of 2.0{\%} (95{\%} CI 0.1-10.4{\%}). The median time to progression was 28 days and the median time on study was 85 days. The majority of patients had a stable performance status while on study. Of the 51 patients who received at least 1 dose of gefitinib, 13 patients had a dose reduction and 9 patients withdrew because of an adverse event. CONCLUSIONS: There was minimal evidence of single-agent gefitinib activity in CRPC. The treatment was associated with clinically relevant toxicities, which responded to dose interruption or reduction.",
author = "Carmel Pezaro and Rosenthal, {Mark A.} and Howard Gurney and Davis, {Ian D.} and Craig Underhill and Boyer, {Michael J.} and Dusan Kotasek and Benjamin Solomon and Toner, {Guy C.}",
year = "2009",
month = "8",
doi = "10.1097/COC.0b013e31818b946b",
language = "English",
volume = "32",
pages = "338--341",
journal = "American Journal of Clinical Oncology: Cancer Clinical Trials",
issn = "0277-3732",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

An open-label, single-arm phase two trial of gefitinib in patients with advanced or metastatic castration-resistant prostate cancer. / Pezaro, Carmel; Rosenthal, Mark A.; Gurney, Howard; Davis, Ian D.; Underhill, Craig; Boyer, Michael J.; Kotasek, Dusan; Solomon, Benjamin; Toner, Guy C.

In: American Journal of Clinical Oncology: Cancer Clinical Trials, Vol. 32, No. 4, 08.2009, p. 338-341.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - An open-label, single-arm phase two trial of gefitinib in patients with advanced or metastatic castration-resistant prostate cancer

AU - Pezaro, Carmel

AU - Rosenthal, Mark A.

AU - Gurney, Howard

AU - Davis, Ian D.

AU - Underhill, Craig

AU - Boyer, Michael J.

AU - Kotasek, Dusan

AU - Solomon, Benjamin

AU - Toner, Guy C.

PY - 2009/8

Y1 - 2009/8

N2 - OBJECTIVE: To determine whether the oral epidermal growth factor receptor (EGFR) inhibitor gefitinib (ZD1839, Iressa®) has clinical efficacy in patients with castration-resistant prostate cancer (CRPC). METHODS: Multicenter open-label phase 2 study. Fifty-one male patients with CRPC and rising PSA levels were enrolled to obtain the target enrollment of 38 patients who completed at least 3 months of treatment with continuous gefitinib 500 mg/d. The primary end point was the prostate-specific antigen (PSA) response rate, as defined by a confirmed 50% decline in serum PSA. RESULTS: One patient had a confirmed PSA response, giving a response rate of 2.0% (95% CI 0.1-10.4%). The median time to progression was 28 days and the median time on study was 85 days. The majority of patients had a stable performance status while on study. Of the 51 patients who received at least 1 dose of gefitinib, 13 patients had a dose reduction and 9 patients withdrew because of an adverse event. CONCLUSIONS: There was minimal evidence of single-agent gefitinib activity in CRPC. The treatment was associated with clinically relevant toxicities, which responded to dose interruption or reduction.

AB - OBJECTIVE: To determine whether the oral epidermal growth factor receptor (EGFR) inhibitor gefitinib (ZD1839, Iressa®) has clinical efficacy in patients with castration-resistant prostate cancer (CRPC). METHODS: Multicenter open-label phase 2 study. Fifty-one male patients with CRPC and rising PSA levels were enrolled to obtain the target enrollment of 38 patients who completed at least 3 months of treatment with continuous gefitinib 500 mg/d. The primary end point was the prostate-specific antigen (PSA) response rate, as defined by a confirmed 50% decline in serum PSA. RESULTS: One patient had a confirmed PSA response, giving a response rate of 2.0% (95% CI 0.1-10.4%). The median time to progression was 28 days and the median time on study was 85 days. The majority of patients had a stable performance status while on study. Of the 51 patients who received at least 1 dose of gefitinib, 13 patients had a dose reduction and 9 patients withdrew because of an adverse event. CONCLUSIONS: There was minimal evidence of single-agent gefitinib activity in CRPC. The treatment was associated with clinically relevant toxicities, which responded to dose interruption or reduction.

UR - http://www.scopus.com/inward/record.url?scp=69349097177&partnerID=8YFLogxK

U2 - 10.1097/COC.0b013e31818b946b

DO - 10.1097/COC.0b013e31818b946b

M3 - Article

VL - 32

SP - 338

EP - 341

JO - American Journal of Clinical Oncology: Cancer Clinical Trials

T2 - American Journal of Clinical Oncology: Cancer Clinical Trials

JF - American Journal of Clinical Oncology: Cancer Clinical Trials

SN - 0277-3732

IS - 4

ER -